A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) In BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, and High Grade Serous Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Prexasertib (Primary)
- Indications Breast cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Proof of concept; Therapeutic Use
- 21 Mar 2019 Planned End Date changed from 30 Jun 2020 to 20 Dec 2020.
- 21 Mar 2019 Planned primary completion date changed from 28 Jun 2019 to 1 Jun 2020.
- 31 Aug 2018 Biomarkers information updated